Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.47 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP5 | P51878 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP9 | P55211 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.43 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7137705 | 1.00 | CTSL (0.56) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL14513406 | 1.00 | CTSL (0.56) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL29876236 | 1.00 | CTSL (0.56) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL2442227 | 1.00 | CTSL (0.56) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL7141467 | 0.98 | CTSL (0.54) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL7141464 | 0.98 | CTSL (0.54) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL14513411 | 0.92 | CTSL (0.48) | CTSLNR3C1NR3C2PGRSMN1; SMN2 | |
| SCHEMBL14513412 | 0.92 | CTSL (0.48) | CTSLNR3C1NR3C2PGRSMN1; SMN2 | |
| SCHEMBL8742438 | 0.90 | CTSL (0.51) | CTSLNR3C1NR3C2PGRCASP1 | |
| SCHEMBL8742444 | 0.90 | CTSL (0.51) | CTSLNR3C1NR3C2PGRCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0611756-B1 | Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| US-5955491-A | ADMINISTERING CATHEPSIN L INHIBITOR AND BONE RESORPTION INHIBITOR CONTAINING AN ALCOHOL OR ALDEHYDE DERIVATIVE, OR SALT THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | claimed |
| US-5498728-A | OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-12 | — | — | US | claimed |
| EP-0611756-A2 | Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | claimed |
| JP-9208545-A | — | — | None | — | — | JP | disclosed |
| JP-8283221-A | — | — | None | — | — | JP | disclosed |
| JP-7101924-A | — | — | None | — | — | JP | disclosed |
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2016037157-A2 | TARGETING CAPN9/CAPNS2 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20070003522-A1 | Methods and compositions for improved retroviral gene and drug delivery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-01-04 | — | — | US | disclosed |
| EP-0611756-B1 | Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5955491-A | ADMINISTERING CATHEPSIN L INHIBITOR AND BONE RESORPTION INHIBITOR CONTAINING AN ALCOHOL OR ALDEHYDE DERIVATIVE, OR SALT THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| US-5716980-A | PROPHYLACTIC, THERAPY FOR OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
| JP-H09208545-A | ALCOHOL OR ALDEHYDE DERIVATIVE AND ITS USE | TAKEDA CHEM IND LTD | 1997-08-12 | — | — | JP | disclosed |
| US-5639781-A | PREVENT REABSORPTION OF BONE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-06-17 | — | — | US | disclosed |
| JP-H08283221-A | PRODUCTION OF ALDEHYDE DERIVATIVE | TAKEDA CHEM IND LTD | 1996-10-29 | — | — | JP | disclosed |
| EP-0731107-A1 | Production of aldehyde derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-5498728-A | OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| JP-H07101924-A | ALCOHOL OR ALDEHYDE DERIVATIVE AND ITS USE | TAKEDA CHEM IND LTD | 1995-04-18 | — | — | JP | disclosed |
| EP-0611756-A2 | Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | CAPN9, CAPNS1, CAPN2 | CTSL 1444/4885NR3C1 3644/4885NR3C2 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.